$11,219.96 research Payment -- Roche/Genentech to Dr. Susan Taylor

Payment Details

AI-Powered Analysis of This Payment

The following analysis was generated by artificial intelligence to help patients understand the context, significance, and implications of this pharmaceutical payment. This analysis is not medical or legal advice.

Roche/Genentech made a $11.2K research payment to Susan Taylor, a Hematology specialist in City, AL. The payment was associated with Skyrizi. Roche/Genentech made a research payment of $11,219.96 to Dr. Susan Taylor in Hematology. The payment is associated with the drug or device 'Skyrizi'. This payment occurred on December 7, 2025.

Patient Guidance: What This Payment Means for You

This information details a payment made for research purposes related to a specific drug. It does not represent a direct payment for your care. Always discuss your treatment options with your healthcare provider and ask about alternatives.

Payment Context: Is This Amount Normal?

Research payments are common in the pharmaceutical industry to fund studies and advance medical knowledge, and this amount is within typical ranges for such research collaborations.

Regulatory Context: Sunshine Act Requirements

This payment is reported under the CMS Open Payments program, which requires disclosure of financial relationships between drug and device manufacturers and physicians.

Related Topics

This payment is related to the following healthcare transparency topics:

• research-payment
• pharma-company
• physician-payment
• drug-research
• hematology
• skyrizi

Understanding research Payments

Research payments fund clinical trials, research studies, and investigator-initiated research conducted by physicians. These payments are often the largest category and represent a critical part of the drug development process. Research funding is generally considered the most legitimate form of pharmaceutical payment, though potential conflicts of interest can still arise when researchers have financial relationships with the companies whose products they study.

Frequently Asked Questions About This Payment

What was this $11.2K payment for?

This was a research payment of $11.2K from Roche/Genentech to Susan Taylor, categorized as "Research". It was associated with Skyrizi. The payment was reported under the Sunshine Act (CMS Open Payments).

Does Susan Taylor accept pharmaceutical money?

Yes, Susan Taylor received this $11.2K payment from Roche/Genentech. Under the Sunshine Act, pharmaceutical companies must report all payments to physicians exceeding $10. You can view Susan Taylor's full payment history on the CMS Open Payments database or on this site.

Is it legal for doctors to accept pharma payments?

Yes, it is legal for physicians to receive payments from pharmaceutical companies. The Physician Payments Sunshine Act (2010) requires transparency by mandating that companies report all payments exceeding $10 to CMS. These payments include consulting fees, meals, travel, speaking fees, and research grants. The law does not prohibit payments but ensures public disclosure.

Should I be concerned about this research payment?

A research payment of $11.2K typically funds clinical studies and is considered standard academic activity. Payment does not imply wrongdoing, but patients have the right to ask their doctor about pharmaceutical relationships.

How do I talk to my doctor about pharma relationships?

You can ask your doctor directly: "Do you receive payments from pharmaceutical companies?" and "Does this affect which medications you prescribe?" Most doctors will answer honestly. You can also verify payment data yourself through CMS Open Payments (openpaymentsdata.cms.gov). Consider asking about generic alternatives and whether the prescribed medication is the best option regardless of manufacturer relationships.

What types of pharma payments are most concerning?

Ownership interests and large consulting/speaking fees are generally considered more significant than meals or small educational grants. Research payments typically fund clinical studies and are common in academic medicine. The total volume and concentration of payments from a single company may be more telling than any individual payment. Patterns matter more than individual transactions.

Does pharma money affect what my doctor prescribes?

Research shows that even small payments can influence prescribing behavior. Studies published in JAMA Internal Medicine found that physicians who received meals costing as little as $20 were more likely to prescribe the promoted brand-name drug. However, many physician-industry interactions are legitimate professional activities. The key is transparency and awareness.

How does this compare to other doctors in Hematology?

To compare this payment against Hematology averages, check the full specialty breakdown on CMS Open Payments. Payment amounts vary widely by specialty and type. Hematology physicians may receive payments for consulting, speaking, or research that are standard for the field. Individual payments should be evaluated in the context of the doctor's full payment history.

What does this payment reveal about Susan Taylor's relationship with Roche/Genentech?

The payment amount is $11,219.96. This $11.2K research payment is part of the transparency data reported under the Sunshine Act.

Is this payment amount typical for Hematology?

The payment type is 'research'.

What should patients do after learning about this payment?

This information details a payment made for research purposes related to a specific drug. It does not represent a direct payment for your care.

What else should I know about this research payment?

The payment was made by Roche/Genentech.

Related Reports

• View Dr. Susan Taylor's full payment report
• Roche/Genentech full spending report
• Browse all Hematology payments
• Browse all payments in Alabama
• Search for other payments